Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

AnuMed Draws Warning Letter for Unapproved Products, Including Semaglutide

  • Post author:PacConAdmin
  • Post published:September 10, 2024
  • Post category:Uncategorized

The FDA hit AnuMed International with a Warning Letter for marketing multiple unapproved drugs including a “homeopathic” semaglutide for weight loss. Source: Drug Industry Daily

Continue ReadingAnuMed Draws Warning Letter for Unapproved Products, Including Semaglutide

Molecular Diagnostic Group Pushes Back Against FDA Regulation, Filing Court Case

  • Post author:PacConAdmin
  • Post published:September 10, 2024
  • Post category:Uncategorized

The Association for Molecular Pathology (AMP) is taking legal measures to neutralize an FDA final rule that regulates laboratory-developed tests (LDT), filing a lawsuit in the US District Court for…

Continue ReadingMolecular Diagnostic Group Pushes Back Against FDA Regulation, Filing Court Case

J&J on the Hook for $1 Billion Over Breach of Contract, Fraud in Robotics Deal

  • Post author:PacConAdmin
  • Post published:September 10, 2024
  • Post category:Uncategorized

A once promising surgical robotics deal with Auris Health has ended in $1 billion in damages for Johnson & Johnson, with a Delaware judge ruling that the healthcare titan failed…

Continue ReadingJ&J on the Hook for $1 Billion Over Breach of Contract, Fraud in Robotics Deal

Legislative Update — Week of Sept. 9, 2024

  • Post author:PacConAdmin
  • Post published:September 9, 2024
  • Post category:Uncategorized

During the second session of the 118th Congress, FDAnews will track important pending legislation, that has been acted on by Dec. 31, 2023 to keep you updated on laws and…

Continue ReadingLegislative Update — Week of Sept. 9, 2024

Quick Notes: Medical Devices — Sept. 9, 2024

  • Post author:PacConAdmin
  • Post published:September 9, 2024
  • Post category:Uncategorized

This edition of Quick Notes features FDA approval of Neuros Medical’s electrical nerve stimulation device, clearance for Clearmind Biomedical’s neuroendoscopy system for minimally invasive neurosurgery, approval for Illumina’s cancer biomarker…

Continue ReadingQuick Notes: Medical Devices — Sept. 9, 2024

EyePoint Nets FDA Warning Letter for Eye Drug Manufacturing Issues

  • Post author:PacConAdmin
  • Post published:September 9, 2024
  • Post category:Uncategorized

Ophthalmology-focused biopharma EyePoint Pharmaceuticals received an FDA Warning Letter underscoring serious GMP violations at its Watertown, Mass., facility, mostly related to a one-time injection eye drug. Source: Drug Industry Daily

Continue ReadingEyePoint Nets FDA Warning Letter for Eye Drug Manufacturing Issues

FDA Expands Guidance on Patient Preference Information to Include Total Product Lifecycle

  • Post author:PacConAdmin
  • Post published:September 9, 2024
  • Post category:Uncategorized

The FDA offers updated advice to medical device sponsors on how to use patient preference information (PPI) throughout the product lifecycle, in a new draft guidance. Source: Drug Industry Daily

Continue ReadingFDA Expands Guidance on Patient Preference Information to Include Total Product Lifecycle

Regulatory Update — Week of Sept. 2, 2024

  • Post author:PacConAdmin
  • Post published:September 6, 2024
  • Post category:Uncategorized

This week, the FDA published eight medical device classifications — cardiovascular, dental (2), hematology and pathology, neurologic, ophthalmic, orthopedic and physical medicine. Final guidance was issued on nitrosamine impurities. The…

Continue ReadingRegulatory Update — Week of Sept. 2, 2024

Quick Notes: Divestiture and Collaboration — Sept. 6, 2024

  • Post author:PacConAdmin
  • Post published:September 6, 2024
  • Post category:Uncategorized

This edition of Quick Notes features announcements of UCB’s divestiture of its Chinese neurology and allergy business and collaborations between Bayer and NextRNA, Flagship Pioneering and Pfizer, and Adcendo and…

Continue ReadingQuick Notes: Divestiture and Collaboration — Sept. 6, 2024

Berkeley Biologics Draws Warning Letter for Unapproved Bone Matrix Products

  • Post author:PacConAdmin
  • Post published:September 6, 2024
  • Post category:Uncategorized

Richmond, Calif.-based Berkeley Biologics failed to file BLAs for several bone matrix products distributed to medical facilities nationwide and lacked proper screening for tissue donors, among other serious lapses cited…

Continue ReadingBerkeley Biologics Draws Warning Letter for Unapproved Bone Matrix Products
  • Go to the previous page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company